Understanding the Influence of Concomitant Irritable Bowel Syndrome (IBS) on Gastro-Oesophageal Reflux Disease (GORD), Including GORD-related Symptoms, GORD Severity, Oesophageal Motility, and Multi-Channel Intraluminal Impedance-pH Findings.

This research aims to investigate whether there is a link between irritable bowel syndrome (IBS) and acid reflux, particularly whether there is a difference in acid reflux symptoms between people with and without IBS.
IBS is a functional gastrointestinal disorder, which has the same root cause as other functional gastrointestinal disorders that produce symptoms similar to acid reflux. Acid reflux symptoms may be typical (heartburn, regurgitation) or atypical (cough, sore throat, chest pain).
All participants are given two questionnaires: one to categorise them as either IBS or non-IBS, and one to understand their acid reflux symptoms. From this, the project will investigate whether there is a difference in the type (typical/atypical) and severity of acid reflux symptoms between people with and without IBS that attend for diagnostic acid reflux testing at Leeds Teaching Hospitals.
Two factors determine how much acid reflux someone has: the ability of the oesophagus (food- pipe) to move food from the throat to the stomach, and how well the muscle between the oesophagus and stomach works to keep acidic contents from moving back up.
All participants will have a test to see how well the muscles in their oesophagus are working. As there may be a link between IBS and oesophageal function, this project will investigate whether any patterns of abnormal oesophageal function can be identified in IBS patients that might explain their acid reflux symptoms.
Participants will then have a test that measures acid reflux over 24 hours, including the amount of acid and non-acid coming up, how high this reaches in the oesophagus, and whether symptoms are linked to these events.
Analysing these test results against questionnaire answers might help to understand the link between IBS and acid reflux to improve future diagnosis and treatment for the many people that have these conditions.

开始日期2024-10-14

申办/合作机构

Leeds Teaching Hospitals NHS Trust

NCT06481787 / Not yet recruitingN/AIIT

A Single-centre Randomised Controlled Study of 8-week Zuojinwan in Combination With Volnoxan Fumarate for the Treatment of Gastro-oesophageal Reflux Disease Combined With Depression

To evaluate the improvement of symptoms in patients with gastroesophageal reflux disease combined with depression (hepatic and gastric depression-heat type) by Zuojin Wan combined with vornodine fumarate regimen as a control, and to compare the adherence to the medication and the adverse reactions of the patients between the two groups.

开始日期2024-06-30

申办/合作机构

南京医科大学第一附属医院

NCT06317675 / Recruiting临床2期IIT

Osteopathic Manipulative Treatment for Patients Affected by Symptoms Related to Gastro-oesophageal Reflux Disease

To evaluate the effects of osteopathic manipulative treatment in patients affected by symptoms related to gastro-oesophageal reflux disease (GERD)

开始日期2024-02-18

申办/合作机构-

100 项与糜烂性胃食管反流病相关的临床结果

登录后查看更多信息

100 项与糜烂性胃食管反流病相关的转化医学

登录后查看更多信息

0 项与糜烂性胃食管反流病相关的专利（医药）

登录后查看更多信息

163

项与糜烂性胃食管反流病相关的文献（医药）

2024-07-30·Journal of Neurogastroenterology and Motility

Treatment Response With Potassium-competitive Acid Blockers Based on Clinical Phenotypes of Gastroesophageal Reflux Disease: A Systematic Literature Review and Meta-analysis

Review

作者: Seo, Seungyeon ; Jung, Hye-Kyung ; Gyawali, C Prakash ; Kim, Seong Eun ; Jeong, Eui Sun ; Moon, Chang Mo ; Lee, Hye Ah ; Lim, Hyung Seok

Background/AimsGastroesophageal reflux disease (GERD) is typically managed based on the clinical phenotype. We evaluated the efficacy and safety of potassium-competitive acid blockers (PCABs) in patients with various clinical GERD phenotypes.MethodsCore databases were searched for studies comparing PCABs and proton pump inhibitors (PPIs) in clinical GERD phenotypes of erosive reflux disease (ERD), non-erosive reflux disease (NERD), PPI-resistant GERD and night-time heartburn. Additional analysis was performed based on disease severity and drug dosage, and pooled efficacy was calculated.ResultsIn 9 randomized controlled trials (RCTs) evaluating the initial treatment of ERD, the risk ratio for healing with PCABs versus PPIs was 1.09 (95% CI, 1.04-1.13) at 2 weeks and 1.03 (95% CI, 1.00-1.07) at 8 weeks, respectively. PCABs exhibited a significant increase in both initial and sustained healing of ERD compared to PPIs in RCTs, driven particularly in severe ERD (Los Angeles grade C/D). In 3 NERD RCTs, PCAB was superior to placebo in proportion of days without heartburn. Observational studies on PPI-resistant symptomatic GERD reported symptom frequency improvement in 86.3% of patients, while 90.7% showed improvement in PPIresistant ERD across 5 observational studies. Two RCTs for night-time heartburn had different endpoints, limiting meta-analysis. Pronounced hypergastrinemia was observed in patients treated with PCABs.ConclusionsCompared to PPIs, PCABs have superior efficacy and faster therapeutic effect in the initial and maintenance therapy of ERD, particularly severe ERD. While PCABs may be an alternative treatment option in NERD and PPI-resistant GERD, findings were inconclusive in patients with night-time heartburn.

2024-02-01·Gut

Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study

Article

作者: Fass, Ronnie ; Liang, Katherine ; Hill, Hannah ; Udemba, Sharon C ; Song, Gengqing ; Tarabichi, Yasir ; Liu, Benjamin Douglas

BackgroundShorter half-life glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying (DGE) more than GLP-1 RAs with longer half-lives. DGE is a known risk factor for gastro-oesophageal reflux disease (GERD) and its complications.AimTo determine whether short-acting or long-acting GLP-1 RAs are associated with an increased risk of new GERD or GERD-related complicationsDesignWe used the TriNetX global database to identify adult patients with type 2 diabetes mellitus and generated two cohorts totalling 1 543 351 patients on (1) GLP-1 RA or (2) other second-line diabetes medication. Using propensity-score matching, Kaplan-Meier Analysis and Cox-proportional hazards ratio (HR), we analysed outcomes and separately examined outcomes in patients starting short-acting (≤1 day) and long-acting (≥5 days) GLP-1 RAs.Results177 666 patients were in each propensity-matched cohort. GLP-1 RA exposure was associated with an increased risk (HR 1.15; 95% CI 1.09 to 1.22) of erosive reflux disease (ERD). However, this was solely due to short-acting (HR 1.215; 95% CI 1.111 to 1.328), but not long-acting (HR 0.994; 95% CI 0.924 to 1.069) GLP-1 RA exposure. Short-acting GLP-1 RAs were also associated with increased risk of oesophageal stricture (HR 1.284; 95% CI 1.135 to 1.453), Barrett’s without dysplasia (HR 1.372; 95% CI 1.217 to 1.546) and Barrett’s with dysplasia (HR 1.505; 95% CI 1.164 to 1.946) whereas long-acting GLP-1 RAs were not. This association persisted in sensitivity analyses, and when individually examining the short-acting GLP-1 RAs liraglutide, lixisenatide and exenatide.ConclusionStarting shorter-acting GLP-1 RAs is associated with increased risks of GERD and its complications.

2023-11-01·Alimentary pharmacology & therapeutics

Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.

Article

作者: Sharma, Prateek ; Harris, Tom ; Yadlapati, Rena ; Hunt, Barbara ; Smith, Neila ; Armstrong, David ; Fass, Ronnie ; Vaezi, Michael ; Leifke, Eckhard

BACKGROUNDNon-erosive reflux disease (NERD) symptoms are often episodic, making on-demand treatment an attractive treatment approach.AIMSWe compared the efficacy and safety of on-demand vonoprazan versus placebo in patients with NERD.METHODSPatients with NERD, defined as heartburn for ≥6 months and for ≥4/7 consecutive days with normal endoscopy, received once-daily vonoprazan 20 mg during a 4-week run-in period. Patients without heartburn during the last 7 days and with ≥80% study drug and diary compliance were randomised 1:1:1:1 to vonoprazan 10, 20, 40 mg or placebo on-demand for 6 weeks. The primary endpoint was the percentage of evaluable heartburn episodes completely relieved within 3 h of on-demand dosing and sustained for 24 h.RESULTSOf 458 patients in the run-in period, 207 entered the on-demand period. In the vonoprazan 10 mg group, 56.0% (201/359) of evaluable heartburn episodes met the criteria for complete and sustained relief; 60.6% (198/327) in the 20 mg group; and 70.0% (226/323) in the 40 mg group, compared with 27.3% (101/370) in the placebo group (p < 0.0001 versus placebo for each vonoprazan group). By 1 h post-dose, vonoprazan was associated with complete relief of significantly more heartburn episodes compared with placebo. No serious treatment-emergent adverse events were reported.CONCLUSIONOn-demand vonoprazan may be a potential alternative to continued daily acid suppression therapy for the relief of episodic heartburn in patients with NERD.CLINICALTRIALSgov: NCT04799158.

项与糜烂性胃食管反流病相关的新闻（医药）

2024-07-27

·药智网

百亿大药市场火力全开

近日，珍宝岛药业的胃病中药1.1类新药——清降和胃颗粒获批临床，作为我国消化道慢性病中的主要疾病，胃溃疡、胃食管反流等疾病一直困扰着我国绝大多数人，而胃药市场，尤其是中成胃药市场的价值，也渐渐体现了出来。潜力巨大中国的胃药市场基础为中国胃病患者的数量。根据《2019年中国胃病调查报告》的数据，在当时中国13亿人口中，肠胃病患者达到了1.2亿的数量，老年人占70%以上，消化道溃疡发病率为10%，慢性胃炎发病率为30%。根据选取的22152份有效样本（以中青年为主）进行统计，65.55%的被调查者明确表示自己患有胃病，22.18%的患者表示不清楚自己是否有胃病，只有12.27%的人表示自己肯定没有胃病。庞大的胃病患者群体，构成了我国胃药商业化的地基。相关数据显示，2021—2022年中国三大终端六大市场中成药胃药（胃炎、溃疡）合计市场规模已经涨至104亿元。其中城市实体药店终端中成药胃药（胃炎、溃疡）销售额超过27亿元，同比增长2.46%；网上药店终端中成药胃药（胃炎、溃疡）销售额涨至4.4亿元，同比增速达到了70.04%。在2023年中国公立医疗机构终端中成药胃药中，销售额在5亿以上的共有三种，分别是四川好先生攀西药业的康复新液，销售额7亿元以上；扬子江的胃苏颗粒，销售额6亿元以上；湖南科伦制药的康复新液，销售额6亿元以上。同时扩张一般而言，可以把中成药胃药的销售渠道分为线上和线下，线上方面，胃药的总量市场已经非常大，目前正处于稳健扩张的阶段。相关数据显示，2021年在中国城市实体药店终端，中成药胃药的市场规模一直保持正增长态势，而2023年上半年销售额超过14.2亿元，增长率为1.06%，保持着稳中有进的势头。在实体店的top20品牌中，增长最惊人的是上海医药旗下青岛国风药业的快胃片，2023年上半年同比增长了179.34%。此外，李万山药厂的和胃整肠丸增长也超过了100%，目前销售总额已经进入了前三位。比实体店增长更惊艳的，是线上零售。近年来，网上药店快速扩容，美团、饿了么等线上药店与APP带货模式相结合，共同促进互联网＋药店的蓬勃发展，目前来看，该行业仍然处于放量增长的阶段： 2014—2021年CAGR为50.54%。2021年，网上药店药品销售额已达到368亿元，同比增长51.5%，并且在OTC药物中，主要由中成药带动。图片来源：东北证券研究所而在胃药方面，增长率则更加惊人。在网上药店的三个新上榜的top20线上销售药物中，云南植物药业的山楂茯苓颗粒同比增长4005%，陕西方舟制药的养胃舒片同比增长18250%，云南保元堂药业的胃康胶囊同比增长1368.18%。此外，太极集团重庆桐君阁药厂的楂曲平胃合剂更是同比增长130500%，品牌排名首次进入TOP5。后期管线仍可期待如今的胃药市场，不止商业化版图仍在递进，后续管线也在不断发力，去承接仍在扩张的增量市场。其中不乏巨头入场，华东医药的姜百胃炎片便是一例。姜百片，即干姜切片，是指对姜根进行切片、晾干而成，具有温中散寒、解表止痛、止呕清胃、散瘀消肿的功效。该药的研发进入临床II期阶段。健民药业的1.1类新药通降颗粒目前同样处于临床II期阶段。健民药业拥有通降颗粒独立完整自主的知识产权。截至目前，健民药业为其累计研发投入达到了608.1万元。通降颗粒处方源于医疗机构院内制剂，功能主治为疏肝清热，和胃降逆，用于肝胃郁热证。该药在临床前的毒理学研究中已经验证了安全性，安全剂量范围较宽。珍宝岛药业的清降和胃颗粒，目前进度也迎头赶上。该药是珍宝岛药业同北京中医药大学附属东方医院合作开发的人用经验的临床经验方。由北京中医药大学消化内科主任李军祥教授多年来在院内制剂处方基础上进一步优化而来，用于非糜烂性胃食管反流病（NERD）寒热错杂证的治疗。当前NERD的治疗主要是依靠质子泵抑制剂，但某些质子泵抑制剂对某些患者并没有太好的疗效，因此，迫切需要其他药物来填补这个需求空白。而目前尚未有治疗NERD的中成药获批，这给了清降和胃颗粒独一无二的市场机遇。而根据相关数据估算，我国目前已有4000多万NERD患者，也就是说，该市场的市场容量达到了40亿元。参考来源：珍宝岛药业企业公告、东北证券研究所声明：本内容仅用作医药行业信息传播，为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 史蒂文转载开白 | 马老师 18996384680（同微信）商务合作 | 王存星 19922864877（同微信）阅读原文，是受欢迎的文章哦

2024-07-22

·派真生物PackGene

一周要闻丨基因治疗要闻速递第112期

行业动态速览热点聚焦 01 治疗罕见心肌病，Lexeo AAV基因疗法临床积极结果公布！ 7月15日，Lexeo Therapeutics（以下简称“Lexeo”）宣布其在研基因疗法LX2006的中期积极数据。LX2006是一种基于腺相关病毒（AAV）的基因治疗候选药物，旨在静脉注射功能性frataxin基因，用于治疗弗里德赖希共济失调心肌病（FA心肌病）。推荐阅读：行业资讯 | 治疗罕见心肌病，Lexeo AAV基因疗法临床积极结果公布！ 02 恒瑞医药子公司自主研发的AAV双基因药物国内IND获受理 2024年7月17日，恒瑞医药（600276）子公司上海瑞宏迪医药有限公司（以下简称“瑞宏迪”）自主研发的AAV双基因药物RGL-193注射液IND获CDE受理。推荐阅读：恒瑞医药子公司自主研发的AAV双基因药物国内IND获受理 03 原发性纤毛运动障碍mRNA疗法最新进展 ReCode Therapeutics公司前不久宣布，首位患者接受RCT1100治疗，这是一种基于mRNA的全新疗法，目前正在一项1期研究中对由DNAI1基因致病突变引起的原发性纤毛运动障碍（PCD）患者进行评估。推荐阅读：恒瑞医药子公司自主研发的AAV双基因药物完成首例人体给药 04 阿法纳生物HPV相关肿瘤mRNA疫苗AFN0328获临床试验批准 2024年7月18日，据国家药品监督管理局药品审评中心（CDE）官网公示，合肥阿法纳生物科技有限公司（以下简称“阿法纳生物”）与安徽安科生物工程（集团）股份有限公司（以下简称“安科生物”）联合研制的1类新药AFN0328注射液临床试验（IND）申请获得批准，成为国内第二款获批开展临床试验的HPV相关肿瘤mRNA治疗型疫苗，也是阿法纳生物今年第二款获得临床试验批件的mRNA产品。推荐阅读：阿法纳生物HPV相关肿瘤mRNA疫苗AFN0328获临床试验批准创新突破 01 正序生物碱基编辑疗法首次治愈外籍β-地中海贫血患者 2024年7月22日，正序生物宣布，其与广西医科大学第一附属医院合作开展的针对重型β-地中海贫血症的碱基编辑药物CS-101的临床研究成功治愈首位海外来华患者，达到持续摆脱输血依赖超过两个月，总血红蛋白浓度稳定至120 g/L以上，并已回归到正常生活中，实现了中国首次基因编辑治愈外籍患者。推荐阅读：中国首次！正序生物碱基编辑疗法首次治愈外籍β-地中海贫血患者 02 Tessera开发mRNA-LNP+rAAV体内基因编辑策略，有效减少剂量，提高治疗效果 2024年7月8日，基因疗法研发公司Tessera Therapeutics联合悉尼大学研究人员在Molecular Therapy上发表了题为“Sleeping BeautymRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency”的研究论文。研究表明，LNP-AAV组合方式避免了双AAV递送系统带来的转座酶非瞬时表达引起的持续异位和过度转座事件，并有效减少了rAAV载体剂量，实现较传统rAAV更好的基因编辑效果。推荐阅读：Tessera开发mRNA-LNP+rAAV体内基因编辑策略，有效减少剂量，提高治疗效果 03 中因科技重组AAV基因疗法获FDA再生医学先进疗法（RMAT）资格认定近日，北京中因科技有限公司宣布，其自主研发的ZVS101e注射液获得美国FDA再生医学先进疗法（RMAT）资格认定，拟用于治疗由CYP4V2基因突变所致的结晶样视网膜变性（BCD）。推荐阅读：中因科技重组AAV基因疗法获FDA再生医学先进疗法（RMAT）资格认定 04 诺奖团队最新Science论文：利用AlphaFold2发现Cas13的祖先，并解析其结构和功能。 2024年7月18日，2020年诺贝尔化学奖得主、CRISPR基因编辑技术奠基人之一的 Jennifer Doudna 教授在国际顶尖学术期刊 Science 上发表了题为：Structure-guided discovery of ancestral CRISPR-Cas13 ribonucleases 的研究论文。该研究将基于AlphaFold2的人工智能的蛋白质结构预测与传统结构比对程序结合，开发出了一种自动化结构检索，发现了Cas13的祖先——Cas13an，并进一步解析了Cas13an的结构及其作用机制，还将Cas13的起源追溯到与防御相关的核糖核酸酶（ribonuclease）。推荐阅读：诺奖团队最新Science论文：利用AlphaFold2发现Cas13的祖先，并解析其结构和功能资本速递 01 超13亿元！23家国内细胞治疗领域企业获得融资细胞治疗是细胞为基础的再生医学疗法，代表着未来医学发展的趋势。受政策、资金、人才支持，中国医药市场受资本市场的青睐。细胞治疗行业成为中国资本投资热点，给予细胞治疗产业发展资金支持。据不完全统计，2024年迄今为止已有23家细胞领域企业获得融资。推荐阅读：超13亿元！23家国内细胞治疗领域企业获得融资 02 诺华2024H1：两款核药收入近10亿美元，IgA肾病新药Atrasentan申报上市 7月18日，诺华公布了2024年上半年的财务业绩。诺华上半年净销售额为243亿美元，按固定汇率计算同比增长11%；净利润59亿美元，同比增长43%。中国销售额为21亿美元，同比增长29%。推荐阅读：诺华2024H1：两款核药收入近10亿美元，IgA肾病新药Atrasentan申报上市 03 反酸、烧心疗法再获FDA批准；1.22亿美元A轮融资助力注册性临床试验启动近日，Phathom Pharmaceuticals公司宣布，美国FDA已批准Voquezna（vonoprazan）10毫克片剂扩展适应症，用于缓解成人非糜烂性胃食管反流病（non-erosive GERD）相关的胃灼热（又称为烧心）。新闻稿指出，这是Voquezna的第三个FDA批准，它曾被批准用于治疗所有严重程度的糜烂性食管炎（EE），也称为糜烂性GERD，以及与抗生素联合用于根除幽门螺杆菌感染。推荐阅读：反酸、烧心疗法再获FDA批准；1.22亿美元A轮融资助力注册性临床试验启动参考资料： https://mp.weixin.qq.com/s/61-r_Bul4a105EqVedSoDA https://mp.weixin.qq.com/s/AOjVP-bo6CChacSSLlRhlg https://mp.weixin.qq.com/s/VrpSCtXgC3uM_ecqFLvyxA https://mp.weixin.qq.com/s/tcStiBBtMO6KIDcvqEZgpg https://mp.weixin.qq.com/s/Wm4OQlIiqrVHxJP2aZaL9w https://mp.weixin.qq.com/s/vj2Whezs9PoiBf8egXyuzA ttps://mp.weixin.qq.com/s/CJKRxpOdkaw9uL4HT63T2A https://mp.weixin.qq.com/s/Mo5QMn-gpeWXAl_UJcEpfQ https://mp.weixin.qq.com/s/sq0-MDyEgtGQMHrjThqQJw https://mp.weixin.qq.com/s/M2TzLq2r8IESTlj_uYPShQ https://mp.weixin.qq.com/s/c5brd0ntzRQ7kpjx3zFPtA 关于派真生物

临床1期临床申请基因疗法疫苗信使RNA

2024-07-18

·药明康德

反酸、烧心疗法再获FDA批准；1.22亿美元A轮融资助力注册性临床试验启动

▎药明康德内容团队编辑显著减少反酸、烧心，创新疗法再获FDA批准 Phathom Pharmaceuticals公司今天宣布，美国FDA已批准Voquezna（vonoprazan）10毫克片剂扩展适应症，用于缓解成人非糜烂性胃食管反流病（non-erosive GERD）相关的胃灼热（又称为烧心）。新闻稿指出，这是Voquezna的第三个FDA批准，它曾被批准用于治疗所有严重程度的糜烂性食管炎（EE），也称为糜烂性GERD，以及与抗生素联合用于根除幽门螺杆菌感染。这一批准基于PHALCON-NERD-301研究的积极结果，这是一项随机双盲、安慰剂对照的3期临床试验，评估Voquezna治疗非糜烂性GERD成人的疗效和安全性。试验结果显示，Voquezna每日治疗在第4周迅速且显著减少了胃灼热。相比安慰剂，Voquezna在第4周时显著增加了24小时内无胃灼热的天数，这是试验的主要终点。服用Voquezna的患者的平均无胃灼热天数比例为45%，而安慰剂组为28%（p<0.001），中位24小时无胃灼热天数比例分别为48%和17%。 Voquezna是一款新型钾离子竞争性酸阻滞剂，可以竞争性阻滞钾离子与氢/钾离子ATP酶的结合，从而快速抑制胃酸的分泌。注册性临床试验今年启动，新锐完成1.22亿美元A轮融资 NGM Biopharmaceuticals公司日前宣布完成1.22亿美元A轮融资。获得资金将用于启动在研疗法aldafermin的注册性临床试验。Aldafermin是一种工程化改造的FGF19类似物，用于治疗原发性硬化性胆管炎（PSC）。这些资金还将用于完成计划中的NGM120的2期临床试验。NGM120是一种GDF15/GFRAL拮抗剂，用于治疗妊娠剧吐（HG）。这两项试验预计将于2024年第4季度开始。 PSC是一种罕见疾病，会不可逆地损害胆管，导致胆汁酸调节失衡，最终可能导致终末期肝病、肝功能衰竭和胆管癌。FGF19在调节体内胆汁酸水平方面起关键作用。FGF19通过影响两个不同的受体复合物，具有抗炎和抗纤维化作用。Aldafermin通过FGFR4/KLB受体介导的信号通路，可降低胆汁酸产生，减少与PSC相关的炎症和缓解瘙痒。通过FGFR1c/KLB受体介导的信号通路，可能改善PSC患者的肝功能和健康。 ▲Aldafermin的作用机制（图片来源：NGM Biopharmaceuticals公司官网） HG的特征是难以控制的恶心和呕吐（每天多达10到15次），导致脱水、虚弱、体重减轻和营养不良。HG对患者有显著的生理和心理社会影响，导致更高的胎儿丧失和终止率、先兆子痫、早产、低出生体重、胎儿营养不良、和母亲抑郁症。该疾病是妊娠期住院的第二大原因（仅次于早产），通常在随后的妊娠中复发。最近的遗传学研究显示HG与血清中GDF15水平升高之间的联系。NGM120是一种抗体，旨在通过与GDF15的受体GFRAL相结合，阻断GDF15信号传导。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum. Retrieved July 18, 2024, from https://news.ngmbio.com/news-releases/news-release-details/ngm-bio-announces-122-million-series-financing-initiate [2] Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults. Retrieved July 18, 2024, from https://investors.phathompharma.com/news-releases/news-release-details/phathom-pharmaceuticals-announces-fda-approval-voqueznar-0 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床2期临床3期上市批准临床结果